Here’s why a Menlo Park drug company is turning from a rare disease to focus on cancer

Starting with a late-stage clinical trial in ovarian cancer, the 24-year-old company is looking to prove that controlling a hormone found in every organ can have an impact beyond its initial rare disease approval a decade ago.